Month: July 2022

VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) — Patriot Battery Metals Inc. (the “Company” or “Patriot”) (CSE: PMET) (OTCQB: PMETF) (FSE: R9GA) is pleased to announce that it has received final approval from the TSX Venture Exchange (the “TSXV”) to list its common shares (the “Common Shares”) effective upon market open on Thursday, July 14, 2022. The Common Shares will trade under its current symbol “PMET”. No actions are required by Patriot’s shareholders. In connection with the listing on the TSXV, the Common Shares will be delisted from the Canadian Securities Exchange (the “CSE”) after market close on Wednesday, July 13, 2022. Both the TSXV and CSE will issue bulletins announcing the change this week. About Patriot Battery Metals Inc. Patriot Battery Metals Inc. is a mineral exploration company focused on the...

PETAH TIKVA, Israel, July 12, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022. Conference Call and WebcastFollowing the release, Adi Sfadia, Chief Executive Officer, and Gil Benyamini, Chief Financial Officer, will discuss Gilat’s second quarter 2022 results and business achievements and participate in a question and answer session: Date: Tuesday, August 9, 2022Start: 09:30 AM EDT / 16:30 IDTDial-in: US: 1-866-744-5399  International: +972-3-918-0609A simultaneous webcast of the conference call will be available on the Gilat website at www.gilat.com and through this link: https://Veidan.activetrail.biz/gilatq2-2022 The...

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cryomass Technologies Inc. (OTCQX: CRYM), a company preparing to manufacture and operate field-mobile equipment for the handling of harvested cannabis, hemp and other high-value plant material, has qualified to trade on the OTCQX® Best Market. Cryomass Technologies Inc. upgraded to OTCQX from the OTCQB® Venture Market. Cryomass Technologies Inc. begins trading today on OTCQX under the symbol “CRYM.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies....

Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced today that it has dosed its first healthy volunteer in its Phase 1 study of the investigational oral therapy SYNB1353 designed to consume methionine for the potential treatment of homocystinuria (HCU). “We are delighted to continue to advance our pipeline of programs with today’s announcement, a notable milestone as we continue towards three expected clinical readouts in 2022, and a reflection of the...

MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF) (“Troilus” or the “Company”) is pleased to report excellent metallurgical recovery results for Zone 87 as part of the recently concluded pilot plant scale metallurgical testing program on each of the main mineral deposits (Zone 87, J Zone and Southwest Zone) from its Troilus Project in northcentral Quebec, Canada. Approximately 3 tonnes of sample material from each of the main mineral zones were sent to Eriez’s metallurgical test facility in Erie, Pennsylvania last year to validate the recovery of gold, copper and silver using standard gravity and column flotation technology. The latest Zone 87 results, along with the metallurgical recoveries for the Southwest and J zones announced earlier this year (see press releases from February 28 and June...

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (HF) patients with Aquadex® ultrafiltration (UF) in the outpatient setting – the first step toward commercializing this opportunity. The webinar featured perspectives from leading heart failure clinicians from across the U.S.:Ramesh Emani, MD, Interventional Heart Failure Cardiologist and Associate Professor of Clinical Medicine, Division of Cardiology, The Ohio State University – Columbus, OH Detlef Wencker, MD, Advanced Heart Failure Specialists – Dallas, TX Pat Correlli, PA-C, Chief Outpatient Physician’s Associate and...

GREENWICH, Conn., July 12, 2022 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), will hold its second quarter conference call and webcast on Wednesday, August 3, 2022, at 8:30 a.m. Eastern Time. The company’s results will be released after market close on Tuesday, August 2, 2022, and made available on investors.gxo.com at that time. August 2, 2022, marks the one-year anniversary of GXO’s debut on the New York Stock Exchange as the world’s largest pure-play contract logistics provider. Access information: Call toll-free from U.S./Canada: 877-407-8029 International callers: +1 201-689-8029 Conference ID: 13731429 Live webcast at: investors.gxo.com A replay of the conference call will be available until August 17, 2022, by calling toll-free (from U.S./Canada) 877-660-6853; international callers dial +1 201-612-7415. Use the passcode...

Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome (186RNL) drug product intermediate On track to manufacture cGMP materials to support ongoing and planned clinical trials for rare cancers in 2022 and beyond AUSTIN, Texas, July 12, 2022 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it has reached a key milestone on the path to commercialization of Rhenium-186 NanoLiposome (186RNL) as the Company completed the technology transfer and initiation of cGMP manufacturing of the 186RNL drug intermediate with Piramal Pharma Solutions (PPS). Additionally, the intermediate drug product is in stability testing and compliant...